Articles On Rhinomed (ASX:RNO)
Title | Source | Codes | Date |
---|---|---|---|
Health Check: Farewell, adieu as Argent Biopharma holders back ASX delisting
Argent Biopharma packs its bags for London on a one-way ticket Patrys shares slump 50% on cancellation of key drug program Painchek targets US market for its pain detection app Health Check is renowned biotech journo Tim Boreham’s daily... |
Stockhead | RNO | 1 month ago |
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month
ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr... |
Stockhead | RNO | 8 months ago |
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks There were a couple of big news from the world of biotec... |
Stockhead | RNO | 8 months ago |
Weed Week: Iron Mike throws down challenge to Biden, and recent ASX pot winners
Mike Tyson has spoken out against the jailing of cannabis users Iron Mike owns his own cannabis brand called TYSON 2.0 We take a look at the best performing ASX weed stocks over the past month There are currently at least 3,000 individ... |
Stockhead | RNO | 9 months ago |
Closing Bell: Markets up almost 0.1pc on Friday as the cows take control
ASX200 rises by a broken fingernail and just looks flat IT gains offset by Energy losses as uranium stocks get hit hard Really peculiar bunch of small cap winners led by AVA Risk and Venture Minerals Local markets have wavered either... |
Stockhead | RNO | 9 months ago |
Closing Bell: ASX traders happy to take the profit after surprise CPI windfall
The ASX benchmark has ended Wednesday higher after positive inflation data 7 of 11 sectors in the green, IT ahead by circa +2pc Small caps led by Euro Manganese The local market has trimmed the CPI fat of this morning’s gains, after the... |
Stockhead | RNO | 11 months ago |
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Xi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks China’s President Xi is expected... |
Stockhead | RNO | 1 year ago |
Weed Week: Jamaican nettletree could be a new, cheaper option to source CBD, says scientists
Jamaican nettletree is said to contain traces of cannabidiol (CBD) Victoria set to launch a medical cannabis driving trial for patients How ASX weed stocks have performed over the past week and month Scientists in Brazil said they’ve d... |
Stockhead | RNO | 1 year ago |
Closing Bell: ASX has best week ever… or at least since everything crashed last month. So… wait… damn you Friday!
ASX200 closes +1.13% higher Property stocks, Industrials and IT Sector gain more than 2% Small caps led by takeover target MCM The Australian sharemarket has ended the first week of November with another stout performance, momentarily a... |
Stockhead | RNO | 1 year ago |
Closing Bell: Ahead of big date with US cash rate, ASX puts October to bed with brash November debut
ASX200 climbs a very laudable +0.85% Property stocks (+1.9%) and Health Care (+1.24%) have led the gains Small caps led by Loyalty Lithium, TG6 and Tambourah Metals The Australian sharemarket has lifted strongly on the first day of the... |
Stockhead | RNO | 1 year ago |
Weed Week: US House Speaker ousting could boost weed stocks; TGA urged to allow the term ‘medicinal cannabis’
Cannabis stocks could rise after the removal of US House Speaker Montu says TGA has to allow the term ‘medicinal cannabis’ to be used We look at the best performing ASX weed stocks over the past month Some experts believe cannabis stock... |
Stockhead | RNO | 1 year ago |
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff
News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks Goldman Sachs analysts said they will make no... |
Stockhead | RNO | 1 year ago |
Closing Bell: Wall St loses bottle over rates; ASX spits dummy over said lost bottle; China stagnates (a bit less); USD crushes AUD
Benchmark ASX index closes -0.6% lower, but gains for the week ASX Sectors led by Utilities which jumped +5.0% since Monday Small caps led by HOR, FTZ, SWF The ASX200 has closed lower on Friday, ending the session -0.6% lower, but ahe... |
Stockhead | RNO | 1 year ago |
Weed Week: Big win for cannabis as SAFER Banking Act approved; market remains robust in Australia
Big win for cannabis as SAFER Banking Act set to be passed in the US Australia’s cannabis industry remains robust this year, says TGA We look at how ASX weed stocks have performed over the past weeks A huge win for cannabis as US SAFER... |
Stockhead | RNO | 1 year ago |
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it
L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks Be... |
Stockhead | RNO | 1 year ago |
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?
The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks On... |
Stockhead | RNO | 1 year ago |
Weed Week: Growing excitement for cannabis stocks after marijuana rescheduling hopes in the US
Cannabis stocks jumped after marijuana rescheduling recommendation in the US Study in Australia shows cannabis is effective on a range of conditions We take a look at the best performing ASX stocks over the past week Cannabis stocks ope... |
Stockhead | RNO | 1 year ago |
Closing Bell: Torque Metals DOMINATES Tuesday
ASX 200 closes -0.25% lower after RBA holds rates at 4.10% Only Consumer Staples, Healthcare and Industrial Sectors find some green Small caps dominated by Torque Metals Aussie home owners have been given another month of grace time f... |
Stockhead | RNO | 1 year ago |
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…
Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August August was all about earnings, and des... |
Stockhead | RNO | 1 year ago |
Check Up: Australian biotech sector continues to be a magnet for US investors
Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the best and worst performing ASX biotechs over the past month The Australian biotech sector co... |
Stockhead | RNO | 1 year ago |
Weed Week: ‘Welcome to the psychedelic 2020s!’ as market holds breath on key US approval
The US is about to follow Australia’s footsteps and approve psychedelics The FDA is currently awaiting a pivotal survey conducted by MAPS And here’s how the ASX weed stocks have performed over the past week In July of this year, Austral... |
Stockhead | RNO | 1 year ago |
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go
Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month Steve Jobs used to say that the most... |
Stockhead | RNO | 1 year ago |
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback
The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July The Covid-19 pandemic had produced windfalls for and attracted fa... |
Stockhead | RNO | 1 year ago |
Weed Week: Social media platforms scramble to update advertising policies on cannabis products
Social media platforms are rushing to update their advertising policies on cannabis Meta was the most recent platform to do so Australia’s TGA is clamping down on CBD advertising in Australia With regulations on cannabis use moving fast... |
Stockhead | RNO | 1 year ago |
How Bod Science pulled ahead in the race for Australia’s first over-the-counter CBD
Since TGA’s down-scheduling of CBD last year, no products have been sold in Australia But the race to market has been seemingly won by Bod Science following a ‘landmark update’ Stockhead reached out to BOD’s CEO, Jo Patterson Amidst gro... |
Stockhead | RNO | 1 year ago |
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines
Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month The world is anticipating a “game changer” as Brisba... |
Stockhead | RNO | 1 year ago |
Weed Week: Storm before the calm as cannabis market set to boom after SAFE Banking Act passed
The weed industry has slumped as it faces several headwinds But new data suggests the industry will grow significantly over the next decade We take a look at how the ASX weed stocks have performed over the past week As we head into the... |
Stockhead | RNO | 1 year ago |
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends
Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week When we talk about dividend-paying hea... |
Stockhead | RNO | 1 year ago |
Weed Week: A ‘shroom boom’ could see psychedelics follow cannabis’ explosive footsteps
The world is experiencing a ‘shroom boom’ Psychedelics are expected to follow in cannabis’ explosive footstep And here’s how the ASX weed stocks have performed, sorted by winners over the past week For years, people have frowned upon ps... |
Stockhead | RNO | 1 year ago |
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough
Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May There are clear signs the biotech sector is springing back to life after a disappointing 2... |
Stockhead | RNO | 1 year ago |
Check Up: Here’s how diabetes drugs can help you get off the beers and lose weight
Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week Earlier this week, Pfizer surprised the market by say... |
Stockhead | RNO | 1 year ago |
Weed Week: Cannabis helps chronic pain and insomnia, and here’s what the TGA rules say
Research in Australia shows marijuana helps with chronic pain and insomnia The rules around getting prescriptions for medicinal cannabis A quick look at the winners and losers of ASX weed stocks Sufferers of chronic pain and insomnia ha... |
Stockhead | RNO | 1 year ago |
Check Up Budget Edition: Which ASX healthcare stocks will reap benefits from the Budget?
The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit Medicare, telehealth and mental... |
Stockhead | RNO | 1 year ago |
Weed Week: New studies confirm cannabis alleviates cancer pain, cuts need for opioids, and improves sleep
Studies confirm that cannabis relieves pain in cancer patients In addition, cannabis also improves sleep and cognitive function in cancer patients We take a look at the biggest movers in ASX weed stocks over the past week It’s now offic... |
Stockhead | RNO | 1 year ago |
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales
Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s... |
Stockhead | RNO | 1 year ago |
Weed Week: 420 reminds us that cannabis stocks may be down, but by no means out
The 420 Day is unofficially the World Marijuana Day, and we look at the possible origins of this day Cannabis stocks have been falling, but there’s still a lot of promise We take a look at the cannabis stocks on the ASX over the past week... |
Stockhead | RNO | 1 year ago |
Weed Week: Most Aussies still use illicit cannabis, but more are now turning to prescriptions
The number of Aussies using legal instead of illicit medical cannabis is rising The main reason for using prescribed medicinal cannabis was chronic pain, says Sydney Uni survey We take a look at what made the news in ASX weed stocks this p... |
Stockhead | RNO | 1 year ago |
WEED WEEK: Wellnex teams up with Chemist Warehouse for new cannabis products
Chemist Warehouse joins WNX JV to develop new cannabis products Neurotech launches new clinical program for its NTI164 drug in Rett Syndrome InhaleRx nabs approval for Phase 1 IRX211 clinical trial for Complex Regional Pain Syndrome Wel... |
Stockhead | RNO | 1 year ago |
Weed Week: Musk gives the go-ahead for cannabis advertising on Twitter in the US
Twitter to allow cannabis companies to advertise in US states where it’s legal Elixnol comes out on top with CannaCare Health arbitration awarded in their favour Avecho expands CBD soft-gel capsule trials with the Lambert Initiative Twi... |
Stockhead | RNO | 1 year ago |
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care
The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry The US FDA announced last week that:... |
Stockhead | RNO | 1 year ago |
Weed Week: Codeine demand drops when recreational cannabis is legal, study finds
US States who allow recreational cannabis see less codeine demand WA GP wants Snoop Dogg to drop into parliament to chat cannabis reform Neurotech nabs pre-submission meeting with US FDA for CBD drug NTI164 A Cornell University study ha... |
Stockhead | RNO | 1 year ago |
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device
Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past... |
Stockhead | RNO | 1 year ago |
The A to Z of Dr Boreham’s Crucible in 2022
The long and short of 2022 is that it was a frustrating period for the Australian biotech sector but one with its fair share of rewards as the sector’s exponents furthered worthy drugs, diagnostics, devices and doodahs. For the sixth year,... |
Stockhead | RNO | 1 year ago |
Weed Week: Decriminalising cannabis could save Aussie tax payers billions every year
Penington Institute says pot-related law enforcement costs us $1.7 billion a year Local cannabis is missing out on international and domestic market opportunities Aussie medicinal cannabis revenue was around $230 million in 2021 Decri... |
Stockhead | RNO | 1 year ago |
How out of favour Biotech has a PR problem and could learn from Dr Karl
ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and... |
Stockhead | RNO | 1 year ago |
Weed Week: More US states vote to legalise cannabis and Czech Republic to follow in Germany’s footsteps
Two more US states join the 19 that already allow legal recreational cannabis use ECS Botanics’ Victorian medical cannabis facility is safe from flooding in the state, so far Cann looks to commercialise its Satipharm CBD capsules for over-... |
Stockhead | RNO | 2 years ago |
Weed Week: Germany’s plans to legalise cannabis rekindle North American investment spark in Europe
Germany looks to legalise recreational cannabis and US and Canadian companies are paying attention Neurotech reports success with its cannabis-based drug for paediatric autism symptoms ECS Botanics has sold its Tasmanian business and a... |
Stockhead | RNO | 2 years ago |
Check Up: Only two healthcare IPOs from 2021 are gaining ground, could the rest be buying opportunities?
We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month There were 191 ASX IPOs in... |
Stockhead | RNO | 2 years ago |
New study confirms Rhinoswab as preferred method for testing children
Rhinomed (ASX:RNO) says a new study shows that children are reluctant to use a traditional nasal swab for testing and that a new Melbourne-designed alternative is the preferred method of sample collection. |
BiotechDispatch | RNO | 2 years ago |
Check Up: Blood clots are a $55bn opportunity and these 2 ASX stocks are vying for a slice
Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re... |
Stockhead | RNO | 2 years ago |